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Abstract 
Nephrolithiasis involves the supersaturation of a stone-forming solute in urine 
leading to the formation of a calculus. The development of novel therapeutic 
agents for this multifactorial urological disorder has been hindered by lack of a 
practical pre-clinical model. Currently established medical treatments can possess 
unfavorable side effect profiles and inconsistent efficacies in certain metabolic 
milieus. Here, Drosophila melanogaster ̶ an emerging model for calcium oxalate 
nephrolithiasis  ̶was investigated as a potential disease model and high throughput 
drug discovery platform for human uric acid nephrolithiasis. Through disruption of 
the Uro gene and purine-rich dietary manipulation, we successfully demonstrate 
the formation of uric acid calculi in fly malpighian tubules as confirmed by ex vivo 
confocal microscopy, qRT-PCR and scanning electron microscopy. Flies treated 
with standardized concentrations of drug candidates through a novel assay 
identified several compounds with potential anti-lithogenic effects underscoring the 
power of D. melanogaster as a high throughput tool in drug screening for 
nephrolithiasis. 
Keywords 
Nephrolithiasis, hyperuricemia, Drosophila melanogaster, GAL4/UAS system, 
kidney stone disease, confocal microscopy, insect model, microdissection, drug 
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Chapter 1  
1 Introduction 
Nephrolithiasis is a common urological disorder with a lifetime risk of approximately 
7-13% in North America, a figure expected to increase to 30% by 2050.1–3 In the 
United States, the prevalence of stone disease has demonstrated a steady 
increase from 5.2% (1994) to 8.4% (2012).4 Globally, a similar upward trend is 
observed agnostic of age, sex or ethnic background.5 The economic burden of 
nephrolithiasis is substantial with annual direct costs reported as $5.3 billion in the 
United States alone.6 Acute nephrolithiasis related complaints generated 1.3 
million ER visits in the US (2009), with 20% requiring hospitalization.7 In addition 
to these acute complications, kidney stone disease is also reported to be a source 
of chronic morbidity associated with chronic kidney disease (CKD).8–10 Following 
the development of an initial kidney stone, the risk of stone recurrence approaches 
greater than 50% over a period of five years.11 
1.1 Classification of nephrolithiasis 
Nephrolithiasis is most commonly classified by calculus composition (Table 1). 
Epidemiological data in relation to stone disease is highly variable, reflecting the 
complex and multifactorial etiologies of this disorder. In industrialized regions, 
calcium-based calculi are by far the most prevalent, accounting for 80% of all 
kidney stones.12–14 Calcium stones are predominantly composed of calcium 
oxalate (~70%) in either the monohydrate or dihydrate forms, often in combination 
with calcium phosphate. Calcium phosphate is the primary constituent of ~10% of 
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calcium stones.14 Uric acid (UA) calculi are the second most common, responsible 
for ~7-10% of kidney stones although significant variations exist geographically, 
particularly in warmer climates.15,16 Struvite calculi, also referred to as “infection-
related stones” due to their association with urease-positive organism urinary tract 
infections (UTIs), comprise ~10% of kidney calculi.17 The autosomal recessive 
disorder cystinuria occurs due to defective cystine transport secondary to 
mutations in the solute carrier genes SLC3A1 or SLC7A9 and is responsible for 
only ~1% of stones18,19. Much rarer stone compositions include silicon, xanthine, 
protein and drug related stones (triamterene, sulfonamides, indinavir).20  
Stone Potential 
constituents20 
Incidence2 Common etiologies 
Calcium 
oxalate 
Monohydrate 
(Whewellite) 
Dihydrate (Weddellite) 
55-61% Idiopathic, Low urine 
volume, Hypercalciuria, 
Hyperoxaluria, 
Hypocitraturia21 
Calcium 
phosphate 
Brushite 
PO4/CO3 apatite 
3/8-calcium phosphate 
12-13% Ca2+/PO4 metabolic 
disturbances, renal 
tubular acidosis, UTI22 
Uric Acid Uric acid 
Monosodium urate 
8-14% Low urine pH/volume, 
Idiopathic, Diabetes, 
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Hyperuricemia, 
Dietary,23 
Struvite Ammonium-
magnesium phosphate 
2-6% Urease-positive UTIs17 
Cystine Cystine 1-6% SLC3A1/SLC7A9 
mutation18 
Other Drugs (e.g. 
Triamterene), Silicon, 
Xanthine 
<1% Iatrogenic, Xanthinuria24 
Table 1: Classification of nephrolithiasis by composition, incidence and 
etiology (North America) 
1.2 Physicochemical mechanisms of nephrolithiasis 
Despite sizeable nephrolithiasis related costs and morbidity, a complete 
understanding of nephrolithiasis on the molecular level remains tenuous.25,26 
Whilst several recent advancements have been made to elucidate the underlying 
processes involved in stone formation, particularly in relation to calcium and uric 
acid nephrolithiasis (UAN), the complete cascade of events is yet to be 
unequivocally defined.27 Several theories exist to describe the journey from solute 
to calculus, most agreeing with the key starting point of supersaturation of a stone-
forming solute in urine promoting crystal formation or crystallization.28 
Supersaturation itself is initiated by several etiological factors influencing the 
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increased production or reduced excretion of the solute in question. This concept, 
first proposed by Robertson et al. in 1966 has persisted as one integral to stone 
research.29–31 This is closely followed by crystal nucleation, growth, and 
aggregation (Figure 1).32  Low-molecular weight compounds such as citrate, stone 
matrix proteins, pyrophosphate and magnesium can alter the biochemical 
environment of urine and calculi, modulating stone growth and morphology as a 
promoter or inhibitor.33,34 Urinary pH plays a particularly important role in modifying 
the solubility of stone forming solutes in urine.35  
 
 
1.3 Uric acid nephrolithiasis 
Epidemiological data for uric acid stones varies significantly based on geographical 
location.36 Regions within the “stone belt” referring to an area spanning from Egypt, 
Figure 1: Schematic representation of the proposed physicochemical 
mechanisms of nephrolithiasis 
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across the Middle East ending at the Philippines appear to be more commonly 
affected.37,38 Prevalence ranges from 4% (Sweden) and 15% (Germany) to as high 
as 22% and 28.1% in Israel and Pakistan respectively.39–42 It is important to note 
that this data is timeworn (30 years old or more) and new insights into the rapidly 
evolving epidemiology of uric acid nephrolithiasis are warranted.  
1.3.1 Uric acid metabolism 
Purines play an important role in human physiology. They are building blocks of 
the nucleic acids DNA and RNA, are core components of co-enzymes and play a 
role in neurological and muscular function.43 Uric acid is the end-product of purine 
metabolism in humans. In lower order mammals and other organisms, uric acid is 
further metabolized to form the soluble compound allantoin by the enzyme urate 
oxidase (Figure 2).44,45 In humans, the gene encoding for urate oxidase production 
is rendered non-functional due to the presence of two nonsense mutations 
preventing further metabolism to allantoin.46 As a result, humans are 
hyperuricemic relative to other organisms (10-fold increase).47 Uric acid has been 
shown to possess neuroprotective, anti-oxidant and cardioprotective functions 
which may explain the evolutionary advantage conferred by the loss of the urate 
oxidase enzyme and relative hyperuricemia.48–51 Following the generation of uric 
acid, it is freely filtered at the glomerulus and undergoes reabsorption and 
secretion at the site of the proximal tubule via the URAT1 transporter52, ultimately 
being excreted through the renal and gastrointestinal systems.43,53–55  
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Figure 2: Purine degradation pathway in human and non-human species 
1.3.2 Risk factors 
Several risk factors for uric acid nephrolithiasis have been identified (Table 2) 
however low urinary pH or volume, hyperuricosuria and hyperuricemia are the 
most strongly associated.16,56. With regards to the most important risk factor of low 
urinary pH23,56, uric acid stone formers have been shown to have a consistently 
lower urinary pH relative to calcium stone and non-stone formers, despite excreting 
normal or even lower amounts of uric acid relative to these populations.57,58 This 
phenomenon can be explained by exploring the physicochemical interactions of 
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uric acid within acidic and basic environments. Uric acid, a weak organic acid (pKa 
5.3 at 37°C), predominantly exists in the ionic form urate within the plasma 
(physiological pH 7.35-7.45).56 Uric acid itself however is poorly soluble in aqueous 
solutions (~100mg/L) and pH is the single most important determinant of 
solubility.59,60 In contrast, urate is 20 times more soluble.61 The risk of uric acid 
crystallization and thus stone formation is therefore inversely related to urinary pH. 
Hyperuricosuria (24-hour urinary uric acid excretion >600mg/day) can be 
associated with a wide range of causative factors such as a purine-rich diet (e.g. 
consumption of large quantities of red meat), hyperuricemia secondary to primary 
gout and medications.16,36,56 Rarer causes include the congenital causes of 
hyperuricemia such as hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) deficiency.62 Factors contributing to low urine volume such as 
hypovolemia secondary to sweating and chronic diarrhea increases uric acid 
supersaturation and thus the risk of uric acid stone formation.36,56,63 Neoplastic 
disorders and other disorders responsible for a high cell turnover have also been 
identified as potential etiologies.64 More recent advancements in the 
pathophysiology of uric acid nephrolithiasis have identified obesity, type II diabetes 
and the metabolic syndrome to be associated with an increased risk of stones. 
This is thought to be due to the association of these disorders with low urinary pH 
as a result of the renal manifestations of insulin resistance.65–67   
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Risk Factor Etiology 
Low urine volume Chronic diarrhea 
 Low fluid intake 
 Diaphoresis 
Low urinary pH Idiopathic 
 Gouty diathesis 
 Diabetes/Metabolic Syndrome 
 Obesity 
 Chronic diarrhea* 
 Primary gout* 
Hyperuricosuria High-purine diet 
 Primary gout* 
 Congenital disorders 
 Medications 
 High cell turnover disorders 
Table 2 Risk factors and etiologies for uric acid nephrolithiasis (* indicates 
factor contributing to two or more risk factors) 
1.3.3 Symptoms and diagnosis 
The signs and symptoms of uric acid nephrolithiasis are identical to those 
encountered in nephrolithiasis in general which include acute onset colicky 
abdominal pain, renal angle tenderness, nausea and hematuria (presence of blood 
in urine).68 As mentioned previously, a low urinary pH (<5.5) may be seen in uric 
acid nephrolithiasis69. Uric acid calculi are radiolucent on plain radiographs70, 
therefore non-contrast helical computerized tomography (CT) scanning is the 
diagnostic tool of choice71. Stone analysis can be utilized to confirm the 
composition of a uric acid based calculus which can be determined by “wet” 
chemical analysis, FTIR (Fourier Transform Infrared Spectroscopy) and X-ray 
diffraction.72 
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1.3.4 Non-surgical management 
The non-surgical management of uric acid nephrolithiasis includes urinary 
alkalinization, lifestyle modification and pharmacological therapy to reduce net uric 
acid excretion.73 Urinary alkalinization with potassium or sodium citrate/ 
bicarbonate and thus the medical dissolution of uric acid calculi is the first-line 
treatment in most cases. It is often successful (~70% of cases) and relatively 
simple to establish.73–75 For this approach, the urinary pH is maintained between 
6.5-7.0, taking care to avoid overalkalinization of the urine as this is associated 
with an increased risk of developing calcium phosphate calculi. For this reason, 
carbonic anhydrase inhibitors such as acetazolamide which are also highly 
capable of urinary alkalinization are generally reserved for patients intolerant to the 
previously mentioned agents.73,76,77 Lifestyle modification in the context of uric acid 
nephrolithiasis generally refers to nutritional changes such as increasing daily fluid 
intake and a low purine diet.78–80 Other dietary factors, such as the consumption of 
sports drinks and grapefruit and other citrus juices could also play a secondary 
role in the management of uric acid calculi through their alkalinizing and citraturic 
effects.81 More recently, theobromine, a methylxanthine found in cocoa and 
chocolate, has been identified as an inhibitor of uric acid crystallization.82 No other 
urinary inhibitors of uric acid crystallization are currently known apart from some 
saponins and glycosaminoglycans.82 Pharmacological therapy is considered in 
individuals who continue to develop uric acid calculi despite urinary alkalinization 
and lifestyle modification.73,83 Pharmacological agents primarily include the 
xanthine oxidase inhibitors allopurinol and febuxostat.84 Since the discovery of 
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febuxostat by the Japanese pharmaceutical company Teijin in 1998, limited 
advancements have made in the pharmacological management of uric acid 
nephrolithiasis. Thus, significant efforts have been directed towards the 
development of novel drug and drug delivery alternatives due to the potential 
serious adverse effects associated with the use of these agents. These adverse 
effects include life-threatening hypersensitivity reactions, hepatoxicity, bone 
marrow depression and nephrotoxicity.85–87  
1.4 Current models of uric acid nephrolithiasis 
Several models of hyperuricemia and associated uric acid nephropathy have been 
described in the literature. The most prominent amongst these are the canine and 
murine models of UAN. The canine model involves the propensity of a specific 
breed of dog, the Dalmatian, to ubiquitously excrete high amounts of uric acid in 
the urine and as a consequence develop uric acid calculi.88–90 This is thought to 
occur due to a missense mutation in the SLC2A9 gene, responsible for UA 
transport at the proximal tubules although other mechanisms such as defective 
hepatic transport of UA have also been proposed.91,92 Whilst there are several 
advantages to the use of the Dalmatian model such as the similarities between the 
human and canine genome/pathophysiology, the utility of this model is limited as 
only ~25% of dogs with hyperuricemia will develop calculi.93,94 In addition, higher 
costs, ethical considerations and the technical difficulties associated with larger 
mammals apply. A mouse model of hyperuricemia has also been previously 
described. The mouse model of hyperuricemia involves vector mediated disruption 
of the urate oxidase gene.95 Whilst this process is highly capable of generating 
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hyperuricemia (10-fold serum uric acid increase), hyperuricosuria and uric acid 
calculi, undesirable features such as mouse lethality, renal scarring and 
morphological changes consistent with florid renal failure are also seen. A further 
rodent model is the rat model of UAN which involves the dietary or intraperitoneal 
administration of the urate oxidase inhibitor oxonic acid.96–98 The administration of 
oxonate along with dietary uric acid supplementation results in renal calculus 
formation, hyperuricemia and hyperuricosuria. 99–104 In addition, renal architectural 
changes, renal fibrosis, glomerular hypertrophy and cyst formation have been 
noted.98,105 Hyperuricemia can also be induced by adenine and ethambutol 
administration via gavage.106 More recently, hyperuricemia has been induced in 
the tree shrew, a non-rodent mammal of rising research importance, by 
intraperitoneal oxonic acid administration, however it is unclear whether this 
approach results in nephrolithiasis.107 
1.5 Drosophila melanogaster as a translational model 
of human disease 
Drosophila melanogaster (DM), the common fruit fly, has long been known to be a 
powerful tool for modeling human disease (Table 3). The mapping of the full 
genome sequence of Drosophila melanogaster by Celera Genomics and the 
Drosophila Genome Consortium in March 2000 has resulted in the rapid 
acceleration of research investigating human disease processes. 108,109 There is a 
high degree of genetic conservation between humans and D. melanogaster. In 
fact, 75% percent of human disease-related genes have corresponding items in D. 
melanogaster. Out of 2,309 previously described human disease genes, 700 direct 
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homologs are present in D. melanogaster which also reproduce the human 
pathology when disrupted.110  In addition, the organ systems of DM, whilst 
rudimentary, have a remarkable degree of functional and structural similarity to 
those of humans and retain many of the underlying features.111 The application of 
DM as an investigative tool in this capacity can be seen throughout the literature, 
especially over the past thirty years.  
Field of investigation Examples 
Neurology Learning and memory112,113, Frontotemporal 
dementia114, Alzheimer’s115, Epilepsy116, 
Stroke117, Brain tumours118 
Cardiology Heart development119, Congenital heart 
disease120, Cardiomyopathy, Heart Failure121 
Endocrinology Thyroid cancer122, Thyroid physiology123, 
Diabetes124  
Gastroenterology Lipid disorders125, Liver Disease126, Intestinal 
dysbiosis/gut microbiome127 
Nephrology Calcium oxalate nephrolithiasis128, Diabetic 
nephropathy129, Kidney injury and repair130, 
Xanthinuria131 
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Oncology Metastasis/metastatic cascade132, Lung 
cancer133 
Table 3 Selected examples of human pathophysiological insights gained 
from the experimental use of Drosophila melanogaster 
1.5.1 Comparative functional anatomy of Drosophila melanogaster 
and human renal systems 
Specialized excretory systems are a fundamental feature encountered in most 
multicellular organisms. Simplified, these systems aim to maintain biochemical 
homeostasis by performing the basic functions of filtration, tubular reabsorption 
and secretion. In Drosophila melanogaster, the renal system is composed of two 
components: Nephrocytes and malpighian tubules (MTs).134 Nephrocytes are 
collections of cells located around the heart (pericardial nephrocytes) and 
esophagus (garland nephrocytes) that filter fly hemolymph in a manner similar to 
the human glomerulus.131,134,135 Nephrocytes perform this function by virtue of the 
nephrocyte diaphragm; a filtration structure formed by the nephrocyte plasma 
membrane invaginations (foot processes) forming small 30nm slit pores in tandem 
with the nephrocyte basement membrane. Together, the diaphragm and basement 
membrane form a barrier discriminatory to size and charge analogous to the 
human glomerulus.136 The four malpighian tubules consist of three segments 
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(initial, transitional and main segments) and two types of cells (principal and 
stellate cells). (Figure 3) 
 
Figure 3 Schematic representation of (A) Fly malpighian tubule and tubule 
segments (B) Principal and stellate cells, responsible for the bulk of solute 
and ion transport (Reproduced with permission: Denholm, Barry et al. “The tiptop/teashirt Genes 
Regulate Cell Differentiation and Renal Physiology in Drosophila.” Development (Cambridge, England) 140.5 
(2013): 1100–1110. PMC. Web. 29 June 2017.) – HG, hindgut; MG, midgut; BM, basement 
membrane; LK, leucokinin; LKR, leucokinin receptor; SJ, septate junction; DH, Diuretic 
hormone; capa, Capability peptide. 
 Each pair of MTs further modify the urine via solute and ion transport in a manner 
similar to the human nephron ultimately excreting waste via a common ureter 
connected to the fly hindgut.130,131,137 (Figure 4). 
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Figure 4 Functional and structural comparison of: (A) mammalian nephron 
and (C) insect malpighian tubule; podocyte (B) and nephrocyte (D) 
(Reproduced with permission: Weavers, Helen et al. “The Insect Nephrocyte Is a Podocyte-like Cell 
with a Filtration Slit Diaphragm.” Nature 457.7227 (2009): 322–326. PMC. Web. 29 June 2017.) fp, 
foot process; sd, slit diaphragm; nd, nephrocyte diaphragm; bm, basement 
membrane. 
1.5.2 Role as a model of human nephrolithiasis and renal disease 
The emergence of Drosophila melanogaster as a model for human nephrolithiasis 
is a relatively recent innovation. The calcium oxalate nephrolithiasis model was 
first described by Chen et al. in 2011.128 This model relies on the generation of 
calcium oxalate (CaOx) crystals in fly malpighian tubules by dietary administration 
of the lithogenic agents ethylene glycol (EG), hydroxyl-L-proline and sodium 
oxalate. Birefringent CaOx concretions were visualized ex vivo by polarized light 
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microscopy and chemical composition as CaOx was confirmed by scanning 
electron microscopy (SEM)/energy-dispersive X-ray spectroscopy (EDX). It was 
noted that oral administration of potassium citrate ameliorated crystal formation 
and decreased crystal size. Several further advancements have been made since 
the initial description of this model. The effect of commercial citrate containing 
juices was investigated by utilizing the D. melanogaster model of calcium oxalate 
nephrolithiasis and was found to be ineffective in reducing stone burden in 
comparison to potassium citrate.138 In 2015, Chi et al. demonstrated that RNAi 
mediated inhibition of the Xdh gene encoding for xanthine dehydrogenase resulted 
in the formation of concretions in fly malpighian tubules. Through the use of this 
model, the importance of zinc in the mineralization of stones was discovered.139 In 
addition, the D. melanogaster CaOx model has been utilized to identify the role of 
dPrestin (SLC26A6) in luminal oxalate transport by RNAi-mediated silencing of 
dPrestin.140 Drosophila models have also been used to investigate other renal 
diseases, such as the role of podocyte mutations in the development of the 
nephrotic syndrome.141 
1.5.3 Advantages of D. melanogaster as a model of human renal 
disease 
Drosophila melanogaster has occupied a central role in health research over the 
past century.142 The genetic tractability of D. melanogaster in tandem with the high 
degree of genetic conservation between fly and human allows for unparalleled 
investigative ability, manipulation and control through relatively simple 
techniques.143,144 Examples of such techniques include the widely employed 
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GAL4/UAS system which allows for tissue specific gene regulation e.g.  RNAi-
mediated gene silencing.145,146 This system is composed of two components: the 
yeast derived GAL4 gene encoding for the yeast galactose-responsive 
transcription activating factor protein GAL4 and a responding upstream activation 
sequence (UAS). A cross between  GAL4 and UAS fly results in tissue specific 
gene regulation.147 (Figure 5) 
 
Figure 5 The GAL4/UAS system (Reproduced with permission from Duffy, J. B. (2002), GAL4 
system in drosophila: A fly geneticist's swiss army knife. Genesis, 34: 1–15. doi:10.1002/gene.10150) 
Other methods include transposon (small, mobile DNA segment)-mediated 
mutagenesis. Such transposons include P-elements, piggyBacs and Minos, which 
insert into the genome resulting in disruption/misexpression of adjacent genes.148 
In addition, Drosophila melanogaster is amongst the few organisms with a fully 
mapped genome sequence and several online resources are available which 
continuously update genetic and genomic knowledge of the Drosophiladae family 
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of flies. The most prominent amongst these groups is the Flybase Consortium 
which also maintains an active and vibrant community of Drosophila 
researchers.149 Furthermore, online tools such as Homologene (NCBI), 
DRSC/DIOPT (Harvard Medical School) and FlyAtlas (Chintapalli, Wang, Dow 
[University of Glasgow]) are also available to identify tissue specific gene 
expression and human gene homologs. Drosophila melanogaster allows for high 
throughput study owing to the rapid holometabolous reproductive cycle of DM, 
which lasts approximately 11 days at 22 C. Rearing and maintenance is 
inexpensive and requires rudimentary equipment. Fly lines, including transgenic 
flies, are readily available through major Drosophila melanogaster stock centers 
(Bloomington Stock Center, Indiana, USA., Vienna [Vienna Drosophila Research 
Centre] and National Institute of Genetics, Kyoto, Japan). In relation to the 
investigation of nephrolithiasis, DM malpighian tubules are transparent and allow 
for excellent observation of stone disease.111  
1.5.4 Limitations of D. melanogaster renal modelling 
The principal apparent limitation of D. melanogaster in modelling human renal 
disease concerns the structural and anatomical arrangement of the renal functional 
elements in comparison to the human kidney. The D. melanogaster renal system 
has been previously described as an aglomerular system which may have limited 
the use of DM in this role.131,135 The podocyte-like filtration function of D. 
melanogaster nephrocytes has however only recently been described which 
demonstrates a striking resemblance to the human glomerulus.131,134–136 In 
contrast, unlike the human kidney, these filtration elements (nephrocytes) are not 
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intimately linked with the modifying tubules (malpighian tubules) and are located 
at two anatomically distinct sites. This introduces a potential drawback, as a co-
mingling of waste products occurs between the filtered hemolymph and the 
contents of the fly gut along with modified fluid from the renal tubules prior to their 
ultimate excretion.150 This could affect the interpretation of data collected 
qualitatively or quantitatively from the observation of intact malpighian tubules in 
vivo although methods have been devised to isolate the malpighian tubules ex vivo 
to counter this issue.131 In addition, the circulatory system of D. melanogaster is 
an open, low-hydrostatic pressure system driven by a single tube-like heart and 
lacks vascular network.151,152 The delivery of fluid to the renal structures is 
therefore markedly dissimilar to the high-pressure, intravascular system 
encountered in humans. The complexity of the human diet and associated 
metabolic processes are difficult to replicate in a rudimentary invertebrate model 
and as a result, the biochemical milieu encountered in the hemolymph may 
potentially be markedly different in comparison to human plasma and urine. This 
limitation is particularly apparent when considering calcium homeostasis in D. 
melanogaster as due to the lack of a skeletal system, approximately one third of 
the calcium stores of DM are stored within calcium concretions in the anterior 
malpighian tubules.153 Whilst these limitations result in a loss of translational 
potential and must be considered in any human renal modelling involving D. 
melanogaster, a multitude of human processes are either wholly or partly 
conserved in D. melanogaster and the study of these components could provide 
novel insights into the human disease equivalent and further management.110 
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1.6 Objectives and Hypothesis 
1) Generation of uric acid calculi in D. melanogaster malpighian tubules: 
We hypothesize that knockdown or disruption of the Uro gene encoding for 
the enzyme urate oxidase via RNAi-mediated silencing or utilization of a 
mutagenic strain will result in uric acid crystal formation in the malpighian 
tubules when fed a purine rich diet. This will allow for the observation of uric 
acid crystals in the malpighian tubules and fly fecal matter due to their 
negative birefringence under polarized light microscopy. 
2)  Confirmation of intervention efficiency: 
We hypothesize that the Uro gene expression will be decreased in our 
knockdown line versus a wild-type fly and will be detectable by qRT-PCR 
and biochemical methods. 
3) Composition analysis of malpighian tubule concretions versus 
human uric acid calculi: 
We hypothesize that broad-spectrum protease dissolution of the 
malpighian tubules will liberate MT crystals, which can be further analyzed 
by scanning electron microscopy and energy dispersive spectroscopy 
(EDX) against pulverized human uric acid calculi. 
4) Development of a novel in vivo high throughput drug screening assay: 
We hypothesize that a suspended cover slip in fly housing will allow for the 
collection of fly fecal matter. In silico analysis of birefringent area versus 
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fecal area will allow us to perform a semi-quantitative analysis of stone 
burden. We hypothesize that treatment with the xanthine oxidase inhibitor 
allopurinol will reduce stone burden and that the treatment of flies from a 
nutraceutical drug library of 120 compounds will identify drug candidates for 
future study.  
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Chapter 2  
2 Materials and Methods 
Studies involving the use of the invertebrate D. melanogaster are currently exempt 
from requiring prior approval by an animal ethics board. All animals were handled 
humanely in accordance with the Canadian Council on Animal Care (CCAC) 
guidelines (“Guide to the care and use of experimental animals”, 1993). 
All fly stocks were sourced from the Bloomington Stock Center, Indiana, USA 
(http://fly.bio.indiana.edu). Canton S flies (Stock #64349) were utilized the wild-
type control. Experiments involving the generation of uric calculi utilized the fly line 
PBac{WH}Urof04888 (Stock #18814) from the Exelixis Collection of transposon 
insertions. The RNAi fly line UAS-Uro (Stock #67300) along with the GAL4 driver 
GAL4-Uro (Stock #44416) was used to obtain pilot data. Statistical analysis was 
performed with GraphPad Prism 6 Software (GraphPad). 
2.1 Rearing and maintenance of D. melanogaster 
All fly stocks were housed in pre-divided trays within wide fly vials (Genesee 
Scientific Corporation, CA). Stocks were maintained in a temperature controlled 
environment (27 C) in a dedicated Drosophila incubator (DigiTherm® Drosophila 
Incubator, Tritech Research Inc.) (Figure 6). A 12-12-hour light-dark cycle and 
humidity of ~30% was maintained. A supplementary stock of flies was maintained 
at room temperature. Daily checks were performed to assess for bacterial growth 
and for the presence of mold or mites in fly housing. Fly media was changed 
weekly by mass transfer of flies into fresh media. New fly stocks were maintained 
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in quarantine physically separated from fly lines already in use for at least two 
generations to prevent mite infestation. Smaller numbers of unwanted flies were 
disposed of in a fly morgue containing 70% ethanol. For the disposal of larger 
numbers of flies, flies were culled by freezing at -20 C prior to disposal. 
 
Figure 6 Fly vials maintained in Drosophila incubator at 27 C 
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2.2 Preparation of standard and lithogenic fly media 
One-liter volumes of standard fly media were prepared per week. Ingredients were 
weighed into plastic weigh boats using a digital scale (BL 1500S, Sartorius AG, 
Germany) and cooked using a laboratory hotplate in a commercial non-stick 
cooking pot. Following preparation, media was decanted into wide polypropylene 
vials (GEN32-121, Genesee Scientific, California, USA) using a disposable pipette 
and covered with grade 50 cheesecloth (GEN53-100, Genesee Scientific, 
California, USA) whilst cooling. Vials were plugged with cellulose acetate closures 
(Flugs® GEN49-101, Diamed Inc., Ontario, Canada) and rested at room 
temperature overnight to prevent water separation. Vials were then stored at 4 C 
for a maximum duration of 28 days until further use. 
2.2.1 Standard media 
Standard media was prepared according to the Bloomington #1 formulation 
described by the Bloomington Stock Center, Indiana, USA (Table 4). This 
formulation results in a firm media which resists liquefaction secondary to larval 
burrowing. 
Ingredient Quantity 
Distilled Water 1000ml (total) 
Agar (66-103, Diamed Inc.) 5.76g 
Yeast Powder (51475-2.5KG, Sigma 
Inc.) 
17.3g 
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Soy, powder (62-115, Genesee 
Scientific) 
10g 
Cornmeal, yellow (62-100, Genesee 
Scientific) 
73g 
Corn syrup, solid (62-109, Genesee 
Scientific)  
76.9g 
Propionic acid (1368, Sigma Inc.) 5ml 
Tegosept (20-258 Diamed Inc.) 30% 
solution (optional) 
5ml 
Table 4 Ingredients used in the preparation of standard media 
To prepare standard media, 500ml of distilled water was poured into a non-stick 
cooking pot and left on high heat to a rolling boil. Cornmeal and agar were 
combined in a 500ml beaker containing 250ml of distilled water and stirred until a 
slurry was formed. Yeast and powdered soy were stirred in a separate beaker 
containing 250ml of distilled water. The cornmeal/agar mixture was added to the 
boiling water and continuously stirred until a gel-like consistency was achieved. 
Following this, the yeast/soy mixture was added followed by corn syrup solids. The 
media mixture was left under high heat until viscous and allowed to cool. Finally, 
propionic acid was added to the media and mixed thoroughly prior to decanting 
into fly vials (10ml final volume per vial). 
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2.2.2 Lithogenic media   
For the preparation of lithogenic media, standard media was supplemented with 
10g yeast-derived RNA (Sigma-Aldrich, Stock. 10109223001 [Roche]) to yield one 
liter of 1% w/v RNA media. RNA was added to the media mixture following the 
addition of the yeast and soy and mixed thoroughly until dissolved. The quantity of 
RNA added to the media mixture was altered as required to prepare 1%, 2% and 
3% w/v RNA media. 
2.3 Gene disruption and knockdown 
Disruption of the Uro gene was achieved by use of the PBac{WH}Urof04888 fly line 
from the Exelixis Insertion Collection (Bloomington Stock #18814). This fly line 
contains an amorphic allele for the Uro gene due to the mutagenic activity of the 
transposon piggyBac154 and was generated in an effort towards developing a 
complete gene knockdown collection through targeted gene disruption.155,156 It has 
previously been shown that this line possesses a strong loss of function Uro 
mutation.157 This fly line was utilized for all experiments involving the generation of 
uric acid calculi unless stated otherwise. Additionally, a GAL4/UAS system RNAi-
mediated gene knockdown was investigated by crossing newly eclosed flies from 
the fly lines UAS-Uro (Stock #63700 – expressing RNAi for Uro under UAS control) 
and GAL4-Uro (Stock #44416 – donated by J. Dow, expressing GAL4 in the 
principal cells of the malpighian tubules corresponding to the pattern of urate 
oxidase). To knockdown the Uro gene, vials containing larger numbers of dark 
pupae were selected from each fly line and flies collected between 8-12 hours after 
eclosion in a fresh tube containing no media. The flies were then anaesthetized by 
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CO2 narcotization (Flystuff Flowbuddy Flow Regulator with Ultimate Flypad, 59-
122BCU) and sorted by sex under a dissecting microscope (Amscope Inc., Irvine, 
United States). Separated flies were added to holding tubes and kept separated 
for 3 days prior to establishing a cross. The resultant F1 progeny of this cross is 
expected to have decreased Uro expression relative to wild-type flies. 
2.4 Malpighian tubule dissection and extraction 
Flies were euthanized by CO2 narcotization (Flystuff Flowbuddy Flow Regulator 
with Ultimate Flypad, 59-122BCU) and transferred to an empty petri dish in 
preparation for dissection. Approximately 10ml of phosphate-buffered saline (PBS) 
was added to an additional Pyrex petri dish (3160100, Sigma-Aldrich Inc.) lined 
with Sylgard (Dow Corning Inc., Michigan, United States) for dissection. This Petri 
dish was centered under a dissecting microscope (Amscope Inc., Irvine, United 
States) with a ringed light source (Amscope Inc., Irvine, United States, LED 144S) 
to ensure minimal surface glare. Fine Inox steel forceps (Dumont #5, Fine Science 
Tools Inc., Vancouver, Canada) were utilized to transfer each individual fly to the 
dissecting petri dish by gently grasping the thorax in a ventral orientation. Using 
the dominant hand, the anal region was gently grasped and retracted resulting in 
the emergence of the hindgut followed by the malpighian tubules. (Figure 7) The 
hindgut was severed above the ureters. For experiments requiring the recovery of 
only the malpighian tubules, the tubules were severed at the ureteric junction. 
Dissected flies were placed onto a wet sponge. The dissecting forceps were 
cleaned and dried prior to repeating this process.  
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Figure 7 Malpighian tubule dissection technique (HG - Hindgut, Arrow 
indicates direction of retraction) (Drosophila image courtesy of Nicolas Gompel, adapted 
for use under Creative Commons Attribution NC 3.0 Unported) 
2.5 Quantitative real-time PCR (qRT-PCR) 
Samples were prepared for qRT-PCR by the dissection and extraction of 30 
malpighian tubules from the fly lines Urof04888 and wild-type Canton S in triplicate 
for each group (n=90/group). Six 1.5ml snap top Eppendorf tubes containing 400ul 
of RNAlater (Sigma Inc., R0901-100ML) were prepared and stored on ice into 
which malpighian tubules were suspended. If RNA extraction could not be 
performed the same working day, samples were stored at -80 C and thawed on 
ice as necessary. PBS was added to each tube in a 1:1 ratio with RNAlater and 
centrifuged at 15,000 x g for 5 minutes (Eppendorf Minicentrifuge 5548). The 
supernatant was removed leaving the malpighian tubule pellet at the base of the 
tube undisturbed. The pellet was disrupted and homogenized using a disposable 
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micropestle. RNA was extracted by using the RNAeasy Plus Mini Kit (Qiagen, 
United States) as per the manufacturer’s instructions. Total RNA was quantified 
using a Nanodrop spectrophotometer (Thermofisher Scientific, United States).  
One microgram of RNA was reverse transcribed to cDNA with qScript™ cDNA 
Synthesis Kit (Quanta BioSciences, United States). Real time amplification of 10ng 
cDNA was performed by the QuantStudio 5 Real-Time PCR system 
(ThermoFisher Scientific, United States). Each well was loaded with 5μl of SYBR-
green master mix (PowerUp SYBR green, Thermo Fisher Scientific), 1μl of each 
forward and reverse primers (10μM, Thermo Fisher Scientific), 2μl of nuclease free 
water and 1μl of cDNA. PCR program and conditions consist of 1 cycle of hold 
stage (50°C for 2 minutes, 95°C for 2 minutes), 40 cycles of PCR stage 
(denaturation at 95°C for 15 seconds, annealing at 60°C for 1 min) and 1 cycle of 
melt curve stage (95°C for 15 seconds, 60°C for 1 minute and 95°C for 1 second). 
Sequence specific primers were used for amplifying the Uro gene and are as 
follows, Forward primer: 5’-GATTCGCAGAAGAACACCGTC-3’; Reverse primer: 
5’-TACGCCTCCACATGAACGTG-3’). β-Actin acted as the housekeeping gene 
(Forward primer: 5’-CTCTGCGGACGCACAATTC-3’; Reverse primer: 5’-
TGCAACCAGTCGTCATCTGC-3’). Relative gene expression was calculated from 
cycle threshold values by CT method. Data for relative gene expression Uro 
between Urof04888 and wild-type Canton S was collected through the results of 
three independent experiments. 
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2.6 Determination of the presence of birefringent 
concretions in fly malpighian tubules and fecal matter 
To assess the presence or absence of birefringent concretions in fly malpighian 
tubules and fecal matter, 20 Urof04888 flies were anaesthetized and placed in vials 
containing 1, 2 and 3% w/v RNA and standard medium in triplicate. Wild-type 
Canton S was used as a negative control. The cellulose acetate vial closures were 
scored centrally with a disposable blade to a depth of ~2cm. A clear cover slip was 
inserted into the scored area and suspended in each fly vial to provide a vertical 
surface for the collection of fly fecal matter. Each group of flies was allowed to 
incubate for a period of 10 days after which the malpighian tubules and cover slips 
were harvested from each group and mounted on to charged glass slides 
(Superfrost® Plus Microscope Slides, VWR). Each glass slide was prepared for 
the mounting MTs by pipetting five small droplets (~20ul) of PBS on to the slide to 
prevent dehydration and degradation of the tubules. Individual droplets were used 
to mount MTs from a single fly to prevent the MTs from bunching together, 
improving visualization during microscopy. Tubules were considered crystal 
positive if birefringence coverage extended over one or more tubule segments to 
account for any naturally occurring calcium concretions in fly MTs. Suspended 
cover slips were harvested from each fly vial and dry mounted directly on to glass 
slides in pairs in preparation for microscopy (Figure 8). 
2.6.1 Ex vivo imaging of fly malpighian tubules and fecal matter 
Prepared slides were centered under a confocal microscope (Nikon A1 Confocal 
Microscope System, Nikon Corp., Japan) at 4X magnification with the transmitted 
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detector (TD) imaging mode enabled for polarized light microscopy. In addition, 
fluorescence data was obtained at a single wavelength (EGFP 488nm) to provide 
contrast. The 4X setting was enabled via the optical configurations (OC panel) and 
the pinhole was set to 5.3 AU. For the EGFP channel, the gain was set at 105 with 
an offset -13 and a power of 7.00. For the TD channel, the gain was set at 110 with 
an offset of -30. The slide was scanned in the resonant mode to bring objects into 
focus after which the Galvano mode was selected at 2048 pixels and a pixel dwell 
of 1.2. In the resonant mode, these settings may generate an image which is 
excessively bright which is corrected in the Galvano mode at the correct pixel 
dwell. Focus and image plane were finely adjusted using the mouse scroll wheel 
until the optimal image was obtained. 
 
Figure 8 Fly fecal matter collection and microscopy 
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2.7 Stone isolation and scanning electron 
microscopy/energy dispersive X-ray spectroscopy 
(SEM/EDX)  
To isolate stones in preparation for scanning electron microscopy (SEM) and 
analysis of composition, a large quantity of Urof04888 flies (n=150) were dissected 
following incubation in 1% w/v RNA media for a period of 10 days. The malpighian 
tubules were suspended in 400ul PBS in a single 1.5ml Eppendorf tube. This 
sample was centrifuged at 15,000 x g for 5 minutes to form a malpighian tubule 
pellet at the base of the Eppendorf tube. The supernatant was removed taking care 
not to disturb the pellet. Following this, 500ul of Proteinase K solution (Proteinase 
K from Tritirachium album, Sigma-Aldrich, P5568-5X1ML) was added to the pellet 
along with 200ul 0.1% Triton-X solution to dissolve organic tubule material. The 
pellet was disrupted with a pipette tip and placed capped in a tube hotplate set at 
37°C for 24 hours. The sample was re-centrifuged at 15,000 x g for 5 minutes 
following which the supernatant was removed. The sample was washed with PBS 
and re-centrifuged two more times to remove any remaining organic material finally 
being suspended in 500ul UltraPure DNase/RNase free water (Invitrogen). The 
sample was then submitted for scanning electron microscopy/energy dispersive x-
ray spectroscopy along with a pulverized human uric acid stone (confirmed by 
FTIR) as a positive control at Surface Sciences, Western University, London, 
Ontario utilizing a Hitachi S4500 Field Emission Scanning Electron Microscope 
(Hitachi Inc, Tokyo, Japan) and Quartz X One EDX system (Quartz Imaging 
Corporation). 
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2.8 Development of high throughput drug screening 
platform 
To assess the effect of bioactive compounds on calculus development within the 
malpighian tubules, a semi-quantitative fecal birefringence assay was developed. 
As the malpighian tubules ultimately exit into the hindgut via a common ureter, we 
observed that flies with birefringent concretions in the malpighian tubules also 
demonstrated birefringent areas in fecal matter. We hypothesized this 
Figure 9 Summary of model validation experiments performed 
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birefringence could be used to qualitatively and quantitatively estimate stone 
burden. To collect fly fecal matter cover slips were suspended from a central score 
carved into the cellulose acetate closures of fly vials. 
2.8.1 Quantification of birefringence in fly fecal matter 
To quantify the area of birefringence normalized to total fecal droplet area, an in 
silico image analysis assay was utilized. Initially, the cover slip under investigation 
was imaged under confocal microscopy. At a 4X magnification, the entire area of 
the cover slip with fecal matter present could not be imaged in a single visual field. 
To counter this, the standard process of capturing serial images (~20 
images/coverslip) was used followed by software-based stitching in NIS-Elements 
(File > Stitch Large Image) for further analysis (Figure 8). As a motorized stage 
was not available for use, this process was conducted manually for each cover 
slip. Each individual image was saved as TIFF file, allowing for the preservation of 
channel data. Separate montages were generated for the transmitted detector 
(polarized light) channel and EGFP (488nm wavelength fluorescent data) channels 
(Figure 10). For quantification, ImageJ (NIH – FIJI package) software was utilized 
by using the particle analysis function, providing numerical output for the area 
occupied by a particle of interest selected via thresholding. For the transmitted 
detector channel, a macro was programmed to allow for efficient “single-click” 
processing (Figure 11). This macro automates the processes of changing the 
image mode to 8-bit grayscale, auto-thresholding via the “Yen” algorithm 
(eliminating user-bias during thresholding), followed by the “Analyze particles” 
function, displaying a numerical output. 
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Figure 11 Macro-based automation of birefringence quantification 
To analyze the EGFP channel (colored) images, the color thresholding function 
was used (Image > Adjust > Color Threshold with the “Dark background” option 
Figure 10 Flowchart depicting in silico particle analysis for birefringent area 
(%) quantification 
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enabled). The brightness sliders on the thresholding interface were manually 
adjusted to capture the total fecal area, taking care to exclude very bright green 
areas representing larvae. This was followed by the executing the “Analyze 
particles” function. The birefringence quotient (BQ) was calculated by dividing the 
birefringent area by the total fecal area, providing a value of birefringence per fecal 
droplet. An empirical qualitative determination of fecal birefringence was also 
made through direct observation to assess the utility of operator-based judgement 
to determine relative birefringence. 
2.8.2  Determination of fecal birefringence under varying purine loads 
To establish controls for future experiments utilizing the fecal birefringence assay, 
20 Urof04888 flies were incubated in 1%, 2% and 3% v/w RNA media in triplicate 
with cover slips suspended from vial closures for the collection of fecal matter for 
a period of 7 days. Cover slips were collected and imaged as mentioned 
previously. 
2.8.3 Determination of effect of DMSO on fecal birefringence 
As future experiments involved the use of dimethyl sulfoxide (DMSO) as a drug 
solvent, the effect of DMSO on birefringence quotient against a negative control 
(distilled water) was determined. 1% w/v RNA was prepared and allowed to cool 
after which 100ul (0.1% v/v) and 200ul (0.2% v/v) of DMSO or distilled water were 
added and mixed using a pipette tip. These volumes were chosen to match the 
final volume of drug added during drug screening to ensure any variations in 
birefringence did not occur as a result of the drug vehicle. 20 Urof04888 flies were 
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incubated for 7 days in each group of media in duplicate following which the 
birefringence quotient was determined as previously described. 
2.8.4 Effect of xanthine oxidase inhibitors on malpighian tubule and 
fecal birefringence 
The effect of the xanthine oxidase inhibitor allopurinol on the formation of 
birefringent concretions in fly malpighian tubules and fecal matter was determined 
by preparing 10ml 2% w/v RNA media as previously described, allowing the media 
to cool and adding allopurinol (Sigma-Aldrich, A8003-5G) from a stock suspension 
of 5mM allopurinol after vigorous vortexing to final concentrations of 0.36, 0.72 and 
1.06mM. 20 Urof04888 flies were incubated in Allopurinol treated media in duplicate 
for 7 days after which the malpighian tubules were dissected and cover slips 
recovered for processing. 
2.8.5 Drug library screening 
A drug library of 120 nutraceutical compounds was procured through collaboration 
with Dr. Paul Spagnuolo, Associate Professor, Department of Food Science, 
University of Guelph. The drug library was received as five 96-well plates loaded 
with plant-based extracts dissolved in DMSO (24 drugs per plate). Each plate was 
stored at -80° C until further use. Each drug was labelled via a numbering system 
to allow for the blinding of prospective researchers, with a master list available 
upon request. To prepare drug treated media, the entire volume of drug provided 
(200ul) was added to 5ml 2% RNA media after cooling and homogenized using a 
pipette tip. Fresh batches of media were prepared for each drug screen and were 
used immediately after preparation. Twenty-four drugs were tested per week by 
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oral administration. This was performed by adding 20 Urof04888 flies to each drug 
vial, incubating for a period of 7 days. Following this, the birefringence quotient 
was quantified via the previously described fecal birefringence assay (Figure 10). 
A drug candidate was considered a “hit” if the reduction in birefringence seen was 
similar in magnitude to that encountered following Allopurinol treatment (little to no 
birefringent material). 
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Chapter 3  
3 Results 
3.1 Ex vivo imaging of DM malpighian tubules  
Urof04888 flies fed 1% RNA medium demonstrated brilliant birefringence in the 
malpighian tubules and fly gut (arrow) (Figure 12 – A, E & Figure 13A) with crystal 
coverage extending over one or more tubule segments. In contrast, a paucity of 
birefringence was noted in Urof04888 MTs fed standard medium (Figure 12 - B, F & 
Figure 13A) with a significant difference noted between groups.  Smaller to no 
areas of birefringence were visualized in wild-type (WT) Canton S fly malpighian 
tubules fed 1% RNA (Figure 12 - C, G & Figure 13B). No birefringence was seen 
in WT fly malpighian tubules when fed standard medium (Figure 12 - D, H & 
Figure 13B). 
 
Figure 12 Polarized light micrograph of Urof04888 and WT flies fed either standard or purine rich 
medium. Fluorescent channel represents malpighian tubule autofluorescence. Arrow indicates fly 
gut. Scale – 50um 
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Figure 13 Malpighian tubule crystal formation in under varying dietary 
conditions (A) Urof04888 flies fed either a standard or purine rich medium 
(n=60/group), p < 0.05, Fisher’s Exact Test (B) Wild-type Canton S flies fed 
either a standard or purine rich medium (n=60/group), p < 0.05, Fisher’s 
Exact test. TS – Tubule segment. 
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Urof04888 fly tubules showed birefringent concretions in all malpighian tubule 
segments although the initial (Figure 14 – A, C) and transitional (Figure 14 – B, 
D) segments appeared to be particularly affected.  
 
 
 
 
 
 
 
3.1.1 Effect of varying purine loads on birefringent concretion 
formation 
Similar distributions of birefringence were seen across all concentrations of purine 
rich media (1%, 2% and 3% w/v RNA) in Urof04888 fly tubules (Figure 15 – A, G). It 
Figure 14 Polarized light micrograph of Urof04888 fly malpighian tubules following 
incubation in purine rich medium (1% w/v RNA) showing segmental distribution of 
birefringent concretions. Initial segment (A,C), Transitional segment (B,D) Scale – 
50um 
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is worth recalling that standard medium, being a yeast-based medium, produced 
relatively smaller or fewer areas of birefringence extending across one or more 
tubule segments in Urof04888 fly tubules.
 
Figure 15 Polarized light micrograph demonstrating Urof04888 fly malpighian 
tubule birefringent concretions under varying purine loads, 1% RNA (A, D), 
2% RNA (B, E) and 3% RNA (C, F) scale bars – 50uM 
3.2 Quantitative real-time PCR 
Quantitative real-time PCR revealed a significant difference in Uro gene 
expression between wild-type Canton S and Urof04888 flies (Student’s t-test, 2-
tailed, p <0.05) with -actin as the housekeeping gene, accounting for a 74% 
downregulation of Uro gene expression between groups (Figure 16).  
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Figure 16 Relative Uro gene expression between wild-type Canton S and 
Urof04888 (Student's t-test, 2-tailed, p <0.05) 
3.3 Scanning electron microscopy and energy-
dispersive spectroscopy 
Birefringent concretions were isolated from Urof04888 fly malpighian tubules as 
previously described and subjected to scanning electron microscopy and energy 
dispersive spectroscopy (Figure 17, A). A pulverized human stone sample 
previously confirmed as being predominantly composed of uric acid by Fourier 
transform infrared spectroscopy (FTIR) was used as a positive control (Figure 17 
- B). Scanning electron microscopy and energy dispersive X-ray spectroscopy of 
isolated MT concretions against a pulverized human uric acid calculus both 
demonstrated similar elemental compositions consisting of carbon (C), nitrogen 
(N) and oxygen (O), consistent with uric acid. Silicon (Si) and Gold (Au) peaks 
seen are a result of noise generated through the mounting process for scanning 
electron microscopy.  
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Figure 17 Scanning electron microscopy of (A) concretion isolated from 
Urof04888 malpighian tubules and (B) Pulverized human uric acid stone with 
respective EDX spectra 
3.4 High throughput drug screening 
3.4.1 Ex vivo imaging of fly fecal matter 
Fly fecal matter collected from Urof04888 flies fed 1% w/v RNA media for a period of 
7 days demonstrated diffuse brilliant birefringence throughout the entirety of the 
fecal volume (Figure 18, D-E). In flies fed standard medium, small foci of 
birefringence were seen, correlating with findings encountered during malpighian 
tubule dissection. (Figure 18, A-C). 
A B 
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3.4.2 Effect of DMSO on fecal birefringence 
No significant difference in fecal birefringence quotient was seen between 0.1% 
and 0.2% v/v DMSO media groups vs. controls (One-way ANOVA, Tukey’s 
multiple comparisons, p >0.05.) (Figure 19). 
Figure 18 Confocal micrograph of Urof04888 fly fecal matter when fed (A-C)  
standard medium, (D-F) 1% w/v RNA medium – scale bars 50um 
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3.4.3 Fecal birefringence under varying purine loads 
No significant difference was seen in fecal birefringence between flies fed 1%, 2% 
and 3% w/v RNA media (One-way ANOVA, Tukey’s multiple comparisons p > 
0.05) (Figure 20). 
   
 
   
 
Figure 19 Fecal birefringence quotient: DMSO vs. controls 
Figure 20 Fecal birefringence quotient under varying purine loads 
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3.4.4 Effect of xanthine oxidase inhibitors on formation of birefringent 
concretions in fly fecal matter and malpighian tubules 
Birefringence quotient was significantly reduced in Allopurinol treated media 
(0.36mM and 0.72mM Allopurinol) against controls. (One-way ANOVA, Dunnett’s 
multiple comparisons, p <0.05) (Figure 21).  
 
 
Figure 21 Fecal birefringence quotient: varying concentrations of 
allopurinol treated media vs. controls (Scale split at 0.003-0.01 on y-
axis) 
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To correlate findings with the quantity of birefringent material in fly malpighian 
tubules, ex vivo polarized microscopy was performed after harvesting malpighian 
tubules from each group. A qualitatively lower quantity of birefringent material was 
noted at 0.36mM (Fig 22 – A), 0.72mM (Fig 22 – B) and 1.06mM (Fig 22 – C) 
allopurinol treated media. Surprisingly, autofluorescent objects (AFOs) were 
observed within the malpighian tubules (arrows) and were more prominently 
featured in 0.72mM allopurinol media along with structural distortions in the 
malpighian tubules. 
3.4.5 Drug library screening 
A pilot high throughput drug screen of 120 plant-derived nutraceutical compounds 
was conducted and revealed several compounds which appeared to exhibit a 
reduction in overall fecal birefringence and thus ameliorated crystal formation. 
Figure 22 Allopurinol-treated media showing reduced birefringent material in 
fly malpighian tubules (A) 0.36mM (B) 0.72mM (C) 1.06mM media – Arrows: 
Autofluorescent objects (AFOs). Scale bars 50um 
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Three compounds appeared to reduce fecal birefringence in a similar manner to 
allopurinol versus controls. (Figure 23) 
 
Figure 23 Representative examples: "Yen" algorithm auto-thresholded raw 
polarized light microscopy images demonstrating fecal birefringence: (A) 
2% RNA control (B) Allopurinol (C) test compound “hit”. Compressed 
composite images, whole image brightness increased by 30% to 
compensate for downscaling. 
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Chapter 4  
4 Discussion and conclusions 
This study broadens the role of Drosophila melanogaster in the investigation of 
human nephrolithiasis. Through relatively simple interventions, we demonstrate 
the formation of uric acid crystals in the malpighian tubules which are readily 
observed using polarized light microscopy. We also describe a non-invasive semi-
quantitative assay involving the imaging of fly fecal matter to determine the effect 
of bioactive compounds and delineate the role of this model in the high throughput 
screening of compounds of interest. This was not previously possible due to the 
constraints of current models of uric acid nephropathy and serves a unique role in 
narrowing focus for further investigation in vitro and in mammalian systems. 
4.1 Ex vivo imaging of DM malpighian tubules 
Confocal microscopy under polarized light showed diffuse brilliantly birefringent 
crystals in PBac{WH}Urof04888 fly malpighian tubules when fed a high purine diet. 
As mentioned previously, this fly line contains an amorphic allele for the Uro gene 
(encoding for the enzyme urate oxidase) as a consequence of the mutagenic 
activity of the transposon piggyBac.154 This fly line has previously been observed 
to have a strong loss of function Uro mutation.157 The phenomenon of crystal 
formation can therefore be explained by the disruption of normal purine 
metabolism. When fed an RNA (or nucleic acid) rich medium, purine nucleotides 
are liberated by enzymatic degradation in the fly gut; a complex and highly active 
digestive system.158 Whilst purines would typically be further metabolized into the 
more soluble compound allantoin, with significantly reduced urate oxidase activity 
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this does not occur, resulting in uric acid crystal formation. As Uro is almost 
exclusively expressed in the malpighian tubules159,160, this is effect appears to be 
particularly pronounced in MTs. Importantly, these crystals also appear to either 
form in or travel between the MTs and the fly gut via the ureteric openings, allowing 
for detection of birefringent concretions downstream. The initial and transitional 
segments of the malpighian tubules appear to be more commonly affected, 
however, this observation may be simply related to the proximity of the main 
segment to the ureteric orifices and result in crystal migration into the hindgut. In 
addition, significantly less birefringent material was seen in Urof04888 fly MTs fed 
standard medium. Although no additional yeast-derived RNA was added to this 
medium, inactivated yeast is a major component of the formulation, which in itself 
introduces a purine load due to the purine rich nature of yeast.161 No significant 
differences in crystal formation in fly MTs were qualitatively observed when purine 
burden was increased suggesting the metabolism of nucleic acids into uric acid 
may be inhibited beyond a certain threshold. This could potentially occur via end-
product non-competitive inhibition. Uric acid, the end-product of purine metabolism 
in humans, has previously been shown to demonstrate dead-end product inhibition 
of xanthine oxidase via steady state kinetic analysis.162 Thus, purine degradation 
may be reduced or delayed as a result of increased uric acid production and 
inefficient elimination. Shunting of the intermediate products of purine degradation 
through an alternative metabolic pathway may also explain these findings however 
apart from the salvage pathway which recycles the products of purine degradation 
for de novo nucleotide synthesis163, such a pathway is yet to be described. 
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Interestingly, trials involving healthy human participants consuming yeast rich diets 
have demonstrated a similar effect wherein hyperuricemia and uric acid excretion 
increase proportionally up to a certain threshold beyond which increasing purine 
burden does not have a significant effect.164 It is worth noting that when fed 3% 
w/v RNA media, fly survival appeared to be significantly impacted. While formal 
lifespan studies are warranted to confirm this effect, on average at end-point, 
significantly fewer (n=3) flies survived in the 3% w/v RNA media in comparison to 
2% w/v (n=18) and 1% w/v RNA media (n=18). Little to no birefringent concretions 
were noted in the malpighian tubules of wild-type flies fed standard or purine rich 
medium reflecting that the disruption of normal purine metabolism appears to be 
responsible for the formation of birefringent crystal formation in the malpighian 
tubules. In addition, pilot data was obtained for RNAi-mediated knockdown of the 
Uro gene. Whilst this method of gene silencing did result in birefringent crystal 
formation, this method required an additional step involving crossing flies prior to 
investigation, decreasing throughput. Therefore, the Urof04888 line was used for 
future experiments to maximize throughput. 
4.2 Quantitative real time PCR and Scanning Electron 
Microscopy/Energy Dispersive X-ray Spectroscopy 
Quantitative real-time PCR showed reduced relative Uro gene expression in 
Urof04888 flies relative to wild-type Canton S corresponding to a 74% 
downregulation in gene expression. This result is consistent with expected results 
as Urof04888 has previously been shown to possess a strong loss of function 
mutation.157 Uro is almost exclusively expressed in the malpighian tubules and 
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therefore loss of function corresponds with uric acid crystal accumulation at this 
site.159  Broad-spectrum protease mediated dissolution of malpighian tubule tissue 
in combination with serial washing and centrifugation yielded a clear sample with 
minimal organic debris appropriate for analysis by SEM. Scanning electron 
microscopy and energy dispersive X-ray spectroscopy of isolated MT concretions 
against a pulverized human uric acid calculus both demonstrated similar elemental 
compositions consisting of carbon (C), nitrogen (N) and oxygen (O), consistent 
with uric acid. Morphologically, crystalline structures isolated from the malpighian 
tubules were distinctly smaller in size (~10um) in comparison to the sizes achieved 
by pulverizing the human uric acid stone sample (~60uM). Additional validation 
experiments such as biochemical probe assays and high-performance liquid 
chromatography (HPLC) based detection of uric acid versus controls are 
warranted to further validate these findings. 
4.3 Ex vivo imaging of DM fecal matter 
Through pilot experiments and our previous work using the calcium oxalate 
nephrolithiasis model in DM, it was determined that birefringent concretions in fly 
MTs migrate into the hindgut, the terminal site of fly excretion, via the common 
ureters. The fly mid and hindgut serve as optimal environments for the continued 
propagation of uric acid crystallization owing to their acidic pH (<4 and 5, 
respectively)158.  Thus, we hypothesized fly fecal matter could be utilized to 
observe variations in stone burden by microscopy under polarized light. Diffuse 
birefringent concretions were confirmed to be present in Urof04888 fly fecal matter 
when fed a purine-rich diet. Much smaller areas of birefringence were seen in flies 
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fed standard medium. No significant differences in fecal birefringence were seen 
in flies fed 0.1% and 0.2% v/v DMSO medium versus controls. In addition, no 
significant differences were noted between groups when fed 1%, 2% and 3% w/v 
RNA media, correlating with observations made during malpighian tubule 
dissection. To further corroborate these findings, reassessment of these groups 
with much larger sample sizes would be useful in addition to lifespan studies.  To 
test the effect of a positive control drug on fecal birefringence, the xanthine oxidase 
inhibitor allopurinol was orally administered to assess if a significant decrease in 
fecal birefringence could be observed. Oxipurinol, the active form of allopurinol, 
forms covalent bonds with the active molybdenum site of the enzyme xanthine 
oxidase forming a oxipurinol-molybdenum complex. This results in the inhibition of 
enzyme function.165,166 Xanthine oxidase is responsible for the conversion of 
hypoxanthine to xanthine and uric acid. The birefringence per total fecal area was 
significantly reduced at concentrations of 0.36 and 0.72mM allopurinol in keeping 
with expected results. Whilst fluorescence confocal microscopy of fly fecal matter 
allows for higher resolution images with improved contrast along with the capturing 
of fluorescence data some disadvantages also exist in comparison to traditional 
light microscopy167 Images may be limited by the optical penetration of the sample 
and some scattered light may not be detected. However, traditional microscopy 
would render determination of total fecal area difficult and the thickness of fecal 
matter is not likely to be an issue in the majority of cases. Direct comparisons of 
both imaging techniques over large sample sizes would therefore be useful to 
assess consistency between methods. 
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4.4 Ex vivo imaging of DM malpighian tubules following 
Allopurinol treatment 
Polarized light confocal microscopy of fly malpighian tubules harvested from 
Urof04888 flies fed purine rich media containing allopurinol at 0.36mM and 0.72mM 
concentrations showed significantly reduced birefringent material in MTs. In 
addition, multiple large autofluorescent objects (AFOs) were noted in the 
malpighian tubules indiscriminate of tubule segment. In flies fed 0.72mM 
allopurinol media, large numbers of these bodies were noted along with sections 
of the MTs where tubule lumen was grossly widened. It has previously been noted 
that the dietary administration of allopurinol in Drosophila melanogaster 
phenocopies the ry (rosy) mutation.168 The rosy locus encodes for the enzyme 
xanthine dehydrogenase (XDH) which is responsible for the catalyzing the reaction 
converting xanthine to uric acid.169,170 XDH is interconvertible to xanthine oxidase 
and both enzymes utilize the same substrates (xanthine, hypoxanthine) but utilize 
different co-factors.170 Ry mutants have previously been shown to accumulate 
hypoxanthine and xanthine due to the deficient functioning of XDH.171,172 
Interestingly, in plant studies investigating point mutations in the xanthine 
dehydrogenase gene, autofluorescent objects were similarly seen in the mesophyll 
cells which were found to be rich in xanthine.173 It is therefore plausible that the 
objects visualized in fly malpighian tubules represent xanthine/hypoxanthine 
particles with the resultant distortions in MT morphology as a result of oxidative 
stress due to the lack of uric acid production (an anti-oxidant). 
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4.5  High throughput drug screening 
The advantages to the use of D. melanogaster as a high throughput drug discovery 
system have long been known and this process has been described extensively in 
the literature.174–177 Several compounds currently used clinically in a therapeutic 
role have analogous mechanisms of action in DM and underscores the power of 
the use of DM in this role.176 The use of DM however introduces some technical 
issues as it may only allow for the modelling of a certain facets of human pathology 
and the interpretation of such assays can be challenging.178 With these limitations 
in mind, we have developed a semi-quantitative assay which allows for high 
throughput screening of bioactive compounds to identify compounds with potential 
anti-lithogenic effects. These compounds could then be further investigated in 
mammalian or in vitro systems, a process which has not been readily possible 
through the use of traditional models of uric acid nephropathy. 
The method described above involving the in silico quantification of birefringence 
per unit area of fecal matter provides a numerical estimate of relative birefringence. 
In addition, relative birefringence can be estimated qualitatively, but this process 
is operator dependent and some training and experience with visualizing raw 
images is required to make accurate deductions. An aggressive threshold for 
identifying candidate compounds is therefore warranted as only very large or small 
relative changes can be determined with accuracy. Through the use of this assay, 
we have identified three such compounds which appear to reduce fecal 
birefringence to a level similar to following treatment with the xanthine oxidase 
inhibitor allopurinol belonging to the bioflavonoid and furanolactone classes of 
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compounds.  At this time, these compounds have not been formally identified for 
proprietary rights reasons. In addition, due to the nature of the screening process 
in which each individual drug was screened on a single occasion to assess the 
utility of this model as a high throughput drug screening system, further 
investigation of these compounds is warranted to assess if these results can be 
replicated in this and other mammalian in vivo systems.   
4.6 Future directions 
The genetic tractability, economic efficiency and general ease of use of D. 
melanogaster helps to bridge a fundamental gap in therapeutic drug discovery in 
nephrolithiasis. The role of DM, however, must be clearly delineated due to the 
limitations encountered in recapitulating a mammalian system. To strengthen 
evidence garnered through the use of DM, further investigation in an in vitro or 
mammalian system can be considered. With reference to nephrolithiasis, interest 
in the direct inhibitors of crystallization is growing. Apart from the recently 
discovered theobromine and some saponins and glycosaminoglycans, no direct 
crystallization inhibitors of uric acid nephrolithiasis are known.82 During the course 
of this study, the utility of utilizing in vitro grown crystals to perform medium to high 
throughput drug screens was briefly investigated. We found that large quantities 
of crystals could be rapidly grown simply in vitro through slow evaporation, slow 
cooling or vapor diffusion. These crystals could also be admixtured with fluorescent 
dyes to allow for direct visualization of crystal morphology (Figure 24, 25, 26). In 
addition, techniques such as turbidimetric assays and visualization under atomic 
force microscopy (AFM) could be used to investigate morphological changes in 
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crystal structure under the action of test compounds. These modalities could be 
utilized as a “pre” or “post” validation screen, further increasing throughput. 
 
Figure 24 In vitro grown uric acid dihydrate (UAD) crystals viewed under polarized 
light microscopy 
 
Figure 25 In vitro grown L-cystine dihydrochloride crystal admixtured with methylene blue 
under polarized light [DAPI (blue) and Alexa594 (red) channels enabled] 
59 
 
 
 
Figure 26 X-ray crystallography of L-cystine based crystal demonstrating 
characteristic disulfide bond 
The use of in vitro grown crystals in a similar manner have been previously 
described in the literature. For example, the role of L-cystine diamides as 
crystallization inhibitors of cystine crystals was discovered through in vitro 
methods.179 To improve the robustness of the uric acid model nephrolithiasis and 
future drug screening, biochemical determination of total uric acid content could 
be considered through the use of enzymatic assays (Uric Acid Assay Kit, MAK077, 
Sigma) or high-performance liquid chromatography (HPLC). This would allow for 
rapid, directly quantifiable result and allow for further validation of the fecal excreta 
assay described above. In addition, lifespan and survival studies under varying 
purine loads with and without drug treatments would be beneficial to determine 
whether any adverse outcomes are observed secondary to crystal formation in 
MTs. Despite significant efforts, only 45% of the genes significantly enriched in D. 
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melanogaster malpighian tubules have estimates of function.180 Recent 
advancements towards expanding our knowledge of the D. melanogaster 
transcriptome in relation to the malpighian tubules have identified several genes 
which appear to contribute to functionally specific domains such as amino acid 
transport.180 Further work in this regard could allow for the development of a D. 
melanogaster model of cystinuria by recapitulating defective cystine transport in 
the malpighian tubules by the knockdown of these genes; expanding the repertoire 
of D. melanogaster based models of nephrolithiasis. In conclusion, Drosophila 
melanogaster is a promising in vivo platform for the modelling of human 
nephrolithiasis which is not restricted to a single stone subtype. These models also 
offer an in vivo platform for drug screening which is amenable to the application of 
much larger chemical libraries. The use of birefringent signals to quantitate calculi 
present in fecal excreta is a key innovation that is cost effective and does not 
require additional staining or additional processing. This also holds implications in 
the future, as other birefringent calculi such as cystine calculi would also be 
amenable to this type of chemical library screen. This screening platform provides 
several avenues of opportunity to identify additional novel compounds of anti-
lithogenic activity, or provide a set of compounds for further evaluation in 
mammalian pre-clinical models. We are confident the translational potential of 
these models will hold future promise in the clinic, changing the face of practice in 
the treatment of nephrolithiasis. 
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